This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Regional enteritis and ulcerative colitis
  • /
  • The Budget Impact of Biosimilar Infliximab (Remsim...
Journal

The Budget Impact of Biosimilar Infliximab (Remsima) for the treatment of autoimmune diseases in five European countries.

Read time: 1 mins
Published:1st Aug 2015
Author: Jha A, Upton A, Dunlop WC, Akehurst R.
Availability: Free full text
Ref.:Adv Ther. 2015;32(8):742-56.
DOI:10.1007/s12325-015-0233-1


Introduction:
Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a considerable impact on patients’ quality of life and healthcare budgets. Biosimilar infliximab (Remsima®) has been authorized by the European Medicines Agency for the management of inflammatory autoimmune diseases based on a data package demonstrating efficacy, safety, and quality comparable to the reference infliximab product (Remicade®). This analysis aims to estimate the 1-year budget impact of the introduction of Remsima in five European countries.

Methods: A budget impact model for the introduction of Remsima in Germany, the UK, Italy, the Netherlands, and Belgium was developed over a 1-year time horizon. Infliximab-naïve and switch patient groups were considered. Only direct drug costs were included. The model used the drug-acquisition cost of Remicade. The list price of Remsima was not known at the time of the analysis, and was assumed to be 10–30% less than
that of Remicade. Key variables were tested in the sensitivity analysis.

Results: The annual cost savings resulting from the introduction of Remsima were projected to range from €2.89 million (Belgium, 10% discount) to €33.80 million (Germany, 30% discount). If any such savings made were used to treat additional patients with Remsima, 250 (Belgium, 10% discount) to 2602 (Germany, 30% discount) additional patients could be treated. The cumulative cost savings across the five included countries and the six licensed disease areas were projected to range from €25.79 million (10% discount) to €77.37 million (30% discount). Sensitivity analyses showed the number of patients treated with infliximab to be directly correlated with projected cost savings, with disease prevalence and patient weight having a smaller impact, and incidence the least impact.

Conclusion: The introduction of Remsima could lead to considerable drug cost-related savings across the six licensed disease areas in the five European countries.

Funding: Mundipharma International Ltd.

 

Read abstract on library site

Access full article